CN112789044A - 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 - Google Patents

使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 Download PDF

Info

Publication number
CN112789044A
CN112789044A CN201980063258.7A CN201980063258A CN112789044A CN 112789044 A CN112789044 A CN 112789044A CN 201980063258 A CN201980063258 A CN 201980063258A CN 112789044 A CN112789044 A CN 112789044A
Authority
CN
China
Prior art keywords
alkyl
optionally
residues
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980063258.7A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·P·布雷斯韦特
S·樱井·南
卡罗伊·尼科利希
桑凯特·V·雷杰
阿诺德·E·J·泰歇特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universal Solvent Co ltd
Original Assignee
Universal Solvent Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universal Solvent Co ltd filed Critical Universal Solvent Co ltd
Publication of CN112789044A publication Critical patent/CN112789044A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980063258.7A 2018-09-26 2019-09-25 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 Pending CN112789044A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
US62/737,017 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
CN112789044A true CN112789044A (zh) 2021-05-11

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980063258.7A Pending CN112789044A (zh) 2018-09-26 2019-09-25 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物

Country Status (15)

Country Link
EP (1) EP3856195A4 (https=)
JP (2) JP7528065B2 (https=)
KR (1) KR20210065950A (https=)
CN (1) CN112789044A (https=)
AU (1) AU2019346456A1 (https=)
BR (1) BR112021004938A2 (https=)
CL (1) CL2021000724A1 (https=)
CO (1) CO2021003713A2 (https=)
EA (1) EA202190463A1 (https=)
IL (1) IL281578A (https=)
MA (1) MA53743A (https=)
MX (1) MX2021002967A (https=)
SG (1) SG11202102105VA (https=)
TW (1) TW202027752A (https=)
WO (1) WO2020069008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113689A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388032A (zh) * 2009-04-08 2012-03-21 贝林格尔.英格海姆国际有限公司 作为ccr3拮抗剂的取代的哌啶
CN104203213A (zh) * 2012-04-04 2014-12-10 勃林格殷格翰国际有限公司 包含ccr3拮抗剂的药物制剂
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
MX2011011080A (es) 2009-04-22 2012-02-23 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
MY199462A (en) * 2017-04-05 2023-10-30 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
CN110636844A (zh) * 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102388032A (zh) * 2009-04-08 2012-03-21 贝林格尔.英格海姆国际有限公司 作为ccr3拮抗剂的取代的哌啶
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
CN104203213A (zh) * 2012-04-04 2014-12-10 勃林格殷格翰国际有限公司 包含ccr3拮抗剂的药物制剂

Also Published As

Publication number Publication date
BR112021004938A2 (pt) 2021-06-01
JP7528065B2 (ja) 2024-08-05
MA53743A (fr) 2022-01-05
TW202027752A (zh) 2020-08-01
CO2021003713A2 (es) 2021-04-08
AU2019346456A1 (en) 2021-04-15
KR20210065950A (ko) 2021-06-04
JP2024153742A (ja) 2024-10-29
EP3856195A4 (en) 2022-06-22
EA202190463A1 (ru) 2021-06-29
CL2021000724A1 (es) 2021-10-15
SG11202102105VA (en) 2021-04-29
MX2021002967A (es) 2021-08-11
IL281578A (en) 2021-05-31
JP2022502441A (ja) 2022-01-11
CA3111433A1 (en) 2020-04-02
EP3856195A1 (en) 2021-08-04
WO2020069008A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP6838085B2 (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
EP3265087B1 (en) Method of treatment with tradipitant
TWI631950B (zh) 藉二氫吡𠯤并吡𠯤治療癌症
BR112014022707A2 (pt) uso de uma quantidade eficaz de um inibidor de quinase tor, método para melhorar os critérios de avaliação, método para a inibição da fosforilação, método para a inibição da atividade de proteína, método para a medição da inibição da fosforilação, kit
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
US20140314673A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
CA3111433C (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
US20200360460A1 (en) Neuroprotective peptide
US20230048888A1 (en) Use of triazolotriazine derivative in treatment of diseases
WO2025188952A1 (en) Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
TW202539621A (zh) 用於治療巴金森氏症的治療劑
HK1248552B (en) Method of treatment with tradipitant

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053020

Country of ref document: HK